** Medical device maker Nevro Corp's shares rise 18.6% to $6.31 premarket
** On Monday, co posted Q3 revenue of $96.9 mln vs analysts' est. of $93.1 mln - data compiled by LSEG
** Co reported Q3 loss per share of 41 cents vs est. for loss of 81 cents per share
** Expects 2024 adj. EBITDA loss of $16 mln to $18 mln, smaller than earlier forecast for loss of $18 mln to $20 mln
** As of last close, stock had fallen ~75% YTD, as NVRO has struggled with weak demand for some of its products and had earlier cut its revenue forecast
** J.P. Morgan says Nevro's management expects outlook to improve in 2025, but brokerage views Nevro as "a 'show me' story" as it tries to reach breakeven
** Twelve of 16 brokerages rate the stock "hold" and 4 "sell" or lower; median PT is $6.50 - LSEG data
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。